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Abstract: During the normal aging process, cytoskeletal changes such as a reduction in density or 
disruption of cytoskeletal components occur that can affect neuronal function. As aging is the biggest 
risk factor for Alzheimer's disease (AD), this study sought to determine how microtubule (MT) 
modification influences cellular response upon exposure to β-amyloid1-42 (Aβ1-42), which is 
implicated in AD. The MT networks of hypothalamic GT1-7 neurons were modified by common 
disrupting or stabilizing drugs, and then the physical and mechanical properties of the modified 
neurons were determined. The MT modified neurons were then exposed to Aβ1-42 and the ability of 
the neurons to cope with this exposure was determined by a variety of biochemical assays. Flow 
cytometry studies indicated that MT disruption reduced the binding of Aβ1-42 to the plasma 
membrane by 45% per cell compared to neurons with stabilized or unaltered MTs. Although the cells 
with disrupted MTs experienced less peptide-membrane binding, they experienced similar or 
increased levels of cytotoxicity caused by the Aβ1-42 exposure. In contrast, MT stabilization delayed 
toxicity caused by Aβ1-42. These results demonstrate that MT modification significantly influences 
the ability of neurons to cope with toxicity induced by Aβ1-42. 
Keywords: Alzheimer’s disease; β-amyloid; microtubules; cellular mechanics; neurodegeneration; 
protein aggregation 
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1. Introduction 
The cytoskeleton plays a critical role in the complex morphology of neurons, intra- and 
intercellular signaling, and organelle transport [1]. In neurons, there are three major cytoskeletal 
components, neurofilaments, actin, and microtubules [2]. Neurofilaments (NFs) are found within the 
axon and dendrites, where they provide structural support, aid in axonal transport, and regulate axon 
diameter [3,4]. The inner plasma membrane of neurons is lined with short fragments of filamentous 
actin (F-actin), while the dendrites and synaptic terminals are rich in F-actin bundles and lattices [1]. 
Lastly, microtubules (MTs) span the length of the axon and protrude into the base of dendrites, where 
they provide structural support, and function as tracks for organelle transport [5]. Importantly, each 
of these cytoskeletal components experience dysfunction with aging that can alter cellular 
functioning [2,6–12]. 
There are many examples of age-related microtubule modification throughout the        
body [10,13–16]. In neurons, exposure to the lipid peroxidation product 4-hydroxy-2(E)-nonenal 
(HNE, a common product of age-related oxidative stress) causes extensive MT disruption, and HNE 
adduction with tubulin prevented polymerization [17]. In human studies, tissue biopsied from 
cognitively healthy adults show an age-dependent decrease in the microtubule density of pyramidal 
neurons [18]. Together, these findings demonstrate that neuronal MTs are critically affected during 
aging. This may have implications for the development of Alzheimer's disease (AD), as AD brains 
display a significant reduction in pyramidal neuron density [19]. MT modification is associated with 
mitochondrial abnormalities [20,21], and reduced axonal transport resulting from MT disruption 
could also contribute to the loss of synaptic connectivity between neurons that causes cognitive 
impairments in AD [18,22]. Considering that aging is the major risk factor for AD [23], it would be 
beneficial to gain a more complete understanding of how age-related MT modification in neurons 
may contribute to disease. 
Two pathological hallmarks of AD are extracellular plaques of amyloid-β (Aβ) and 
intraneuronal neurofibrillary tangles (NFTs) containing the hyperphosphorylated 
microtubule-associated protein Tau (Tau) [24]. Aβ is a 38-43 amino acid long residue that is 
produced from sequential cleavages of the amyloid precursor protein (APP) [25], but Aβ1-40 and 
Aβ1-42 are the most abundant forms. Aβ aggregates themselves are toxic, but their presence is also 
thought to trigger a cascade of events leading to the formation of NFTs [25–27], which ultimately 
causes the deterioration of the neuronal processes and cell death [28–33]. 
In the brains of AD individuals, age-related neuronal modifications are amplified in selectively 
vulnerable regions of the brain, such as the hippocampus and closely related limbic and cortical 
structures [23,34,35]. These changes can contribute to the increased production or decreased 
clearance of Aβ, resulting in Aβ-induced neurotoxicity [23]. Specifically, impaired axonal transport, 
a consequence of age-related MT disruption, has been shown to stimulate the production and 
accumulation of Aβ [36]. Therefore, although it is well known that Aβ has downstream effects on 
Tau and subsequently MT stability, age-related MT disruption may actually be a causative factor in 
AD. Due to the relationship between aging, Aβ, and AD, we sought to determine how microtubule 
modification influences the cellular response to toxicity caused by aggregates of Aβ1-42. To 
accomplish this goal, GT1-7 neurons were treated with a variety of MT stabilizing or destabilizing 
agents, and toxicity associated with exposure to Aβ1-42 aggregates was examined. This work 
provides insight into how MT modification, which is a common feature of the natural aging process, 
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may contribute to the development of AD. 
2. Materials and Methods 
2.1. Cell Culture 
GT1-7 hypothalamic neurons were obtained from Dr. Susan Mayo at the University of 
California, San Diego. Neurons were grown in DMEM medium supplemented with 4.5 g/L glucose, 
110 mg/L sodium pyruvate, 1% penicillin-streptomycin (stabilized with 10,000 units penicillin and 
10 mg streptomycin/mL), 2 g/L sodium bicarbonate, 584 mg/L L-glutamine (Sigma-Aldrich, St. 
Louis, MO), 5 mM HEPES (Fisher BioReagents, Waltham, MA) and 10% HyClone® fetal bovine 
serum (Thermo Scientific, Waltham, MA) [37–41]. Cultures were maintained at 37 °C and 5% CO2. 
For all cell-based experiments, serum concentration was reduced to 5%. 
2.2. Microtubule treatments and Aβ1-42 Preparation 
Colchicine, nocodazole, and paclitaxel (Fisher Scientific) were dissolved in dimethyl sulfoxide 
(DMSO, Fisher Scientific) and further diluted in the appropriate buffer or medium to a final 
concentration of 0.1–10 µM. Neurons were exposed to a microtubule (MT) modifier for 4 hours prior 
to Aβ exposure to ensure cytoskeletal modification. Aβ peptides (Aβ1-42 and FAM-labeled Aβ1-42) 
were purchased from AnaSpec Inc., Fremont, CA. Lyophilized peptides were stored at −20 °C and 
allowed to equilibrate to room temperature for 30 minutes before resuspension in 
1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Fisher Scientific) to 1 mM. The peptide solution was 
sonicated for 10 minutes at room temperature and aliquoted into microcentrifuge tubes. The solution 
was dried and the peptide films were stored at −20 °C until use. Directly before use, HFIP-treated 
peptide films were dissolved in DMSO by pipette mixing, vortexing, and sonication for 10 minutes 
at 37 °C [42]. Peptide solutions were then diluted into the appropriate buffer or medium to a final 
concentration of 5 µM. DMSO exposure to cells never exceeded 1%. 
2.3. Cellular mechanical evaluation via AFM 
Cells were seeded on poly-D-lysine coated glass coverslips and allowed to incubate overnight. 
Neurons were treated with a MT-altering drug or vehicle for 4 hours and then exposed to Aβ for 30 
minutes. Cells were washed and fixed in a glutaraldehyde solution [43]. Coverslips were mounted 
onto the AFM stage and imaged in buffer with a NanoScope V MultiMode scanning probe 
microscope (Veeco, Santa Barbara, CA) equipped with a closed-loop vertical engage J-scanner. 
Experiments were conducted in contact and force volume imaging modes. All images were acquired 
using a VISTAprobe contact mode short cantilever (Nanoscience Instruments, Inc., Phoenix, AZ), 
where the tip radius was 10 nm and the spring constant was calculated via the thermal tuning method 
[38,44]. The same probe was used for all results presented. Scan speed for topography images was 
0.5 Hz with a pixel resolution of 512 × 512. Force curves were acquired at 10 Hz, and force volume 
images had a resolution of 128 × 128 curves. Young's modulus (E) was evaluated using NanoScope 
Analysis software v1.5 (Bruker, Santa Barbara, CA). A Hertz model was applied to determine E, 
where Poisson's ratio was ν = 0.5 [37,43]. A minimum of 9 cells were evaluated for each sample. E 
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values were extracted from both the soma and processes. Histograms were produced in MATLAB 
(Math Works Inc., Natick, MA) and values are given as mean ± standard deviation. Statistical 
significance was analyzed using an unpaired t-test, where a difference at p < 0.05 was considered 
statistically significant. The soma region of the cell was determined from corresponding topography 
images by finding the tallest pixel within the cell body and defining a sampling zone where the 
height of the cell remained within 20% of the height of this tallest pixel. Care was taken to make sure 
that the coverslips on which the cells were attached remained fully hydrated during mounting to the 
AFM. 
2.4. Assessment of Aβ1-42 aggregation state 
To determine the Aβ aggregate morphology, Aβ was prepared as described above and diluted in 
PBS to 5 µM. The solution was spotted onto freshly cleaved mica after 0, 24, and 48 hours of 
incubation at 37 °C. Mica was rinsed with ultrapure water and immediately dried under a gentle 
stream of nitrogen. Ex situ images were acquired via tapping mode AFM with a VISTAprobe silicon 
cantilever with a nominal spring constant of 40 N/m and a resonance frequency of ~300 kHz. AFM 
image analysis was performed using the image processing toolbox of Matlab, as previously described 
[45]. The images were imported into Matlab and flattened to correct for background curvature. Using 
a height threshold, a binary map of the surface was created to locate individual aggregates and by 
implementing pattern recognition algorithms to the binary map, aggregate features were measured 
(height, volume, etc.). 
The SensoLyte® Thioflavin T (ThT) Aβ aggregation kit (AnaSpec, Fremont, CA) was used to 
confirm the absence of fibrillar aggregates in the 5 µM Aβ solution over a 48 hour period. 5 µM Aβ 
was prepared as earlier described and added to an untreated 96 well plate containing a ThT solution. 
Pretreated Aβ from the supplier that is known to rapidly form fibrils was prepared as recommended 
and used as a positive control. The fluorescence intensity was monitored via an Infinite M1000 Pro 
microplate reader (Tecan US, Raleigh, NC) at Ex/Em of 440/484 nm every 10 minutes over 48 hours 
at 37 °C with no shaking to mimic assay conditions. 
2.5. Flow cytometry 
Neurons were seeded in 6-well plates and allowed to incubate overnight. A 4 hour MT or 
vehicle treatment was followed by an 80 minute exposure to FAM-Aβ [46,47]. Samples were 
thoroughly washed to remove any unbound peptide and they were lifted from the surface using a 
0.25% trypsin solution. Neurons were then rinsed and resuspended in cold sorting buffer (1x D-PBS, 
25 mM HEPES at pH 7.0, 2.5 mM EDTA, and 1% bovine serum albumin). The fluorescence 
intensity per cell was assessed with a BD FACSCalibur cytometer and BD FACSDiva v8.0 software 
(BD Biosciences, Franklin Lakes, NJ). 
2.6. Plasma membrane degradation assay 
Neurons were seeded at 10,000 cells/100 µL medium on a tissue culture-treated 96-well plate 
and allowed to incubate for 24 hours. Cells received a MT modifying pretreatment, followed by an 
Aβ exposure for an additional 24 or 48 hours. Ethidium homodimer-1 (EthD-1, Molecular Probes, 
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Grand Island, NY) was used to evaluate plasma membrane degradation according to the 
manufacturer's protocol. EthD-1 enters neurons with compromised membranes to produce a bright 
red fluorescence upon binding to nucleic acids. As a control, a group of vehicle-treated cells received 
a treatment with 70% methanol 30 minutes prior to EthD-1 exposure. A 6 µM stock of EthD-1 was 
prepared in Dulbecco's phosphate buffered saline (D-PBS, Fisher Scientific) and 100 µL was added 
to each well for a final concentration of 3 µM. The samples were incubated for 45 minutes at room 
temperature and the fluorescence intensity was measured at Ex/Em of 495/635 nm. All assay 
measurements were performed at least in triplicate. 
2.7. MTT reduction assay 
Samples were prepared exactly as described for the plasma membrane degradation assay, and 
MTT reduction was evaluated via the MTT assay kit (Abnova, Walnut, CA). The MTT assay 
involves the conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to 
insoluble formazan crystals. The tetrazolium salt MTT reduction is dependent on reducing agents, 
NADH and NADPH, produced by metabolically active cells. MTT reagent was added to each well 
according to the manufacturer's protocol and the samples were incubated for 4 hours at 37 °C. The 
crystals were solubilized by adding 100 µL of the provided buffer solution to each well with gentle 
shaking for 1 hour at room temperature. The absorbance was measured at 570 nm. 
2.8. Statistical analysis 
Plasma membrane degradation and MTT reduction was analyzed using GraphPad Prism v5 
software (GraphPad Software Inc., La Jolla, CA). Statistical significance was determined using a 
one-way analysis of variance (ANOVA) with Turkey's multiple comparison test. Differences at p < 
0.05 were considered statistically significant. All assay data is plotted as a ratio of value/baseline 
(vehicle control) where error bars reflect standard error of the mean. 
3. Results 
3.1. Microtubule modification alters the physical and mechanical properties of neurons 
To determine how the MT network influences the ability of Aβ1-42 aggregates to cause toxicity, 
it was first necessary to induce MT modification by common disrupting or stabilizing treatments. 
Hypothalamic GT1-7 neurons were treated with a MT disruptor (colchicine or nocodazole) or 
stabilizer (paclitaxel) for four hours at 0.1, 1.0, and 10.0 µM. Both colchicine and nocodazole cause 
MT depolymerization at high concentrations [48], while paclitaxel mechanically stabilizes MTs by 
binding to β-tubulin [49]. After four hours of treatment, the physical and mechanical properties of the 
neurons were examined. Neurons with chemically disrupted MTs displayed morphological changes, 
specifically in reducing extensions of the plasma membrane that are commonly considered to model 
neurites in the GT1-7 cell line (Figure 1). This observation is in agreement with other studies that 
reported MT disruption induced morphological alterations in the periphery of PC-12 and endothelial 
cells [50–52]. Cells treated with paclitaxel did not display a reduction in extensions of the plasma 
membrane, as would be expected with stabilization of MTs. 
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Figure 1. Morphological changes of GT1-7 neurons treated with MT modifiers. Neurons 
were exposed to the vehicle, a MT-depolymerizers (colchicine and nocodazole), or a 
MT-stabilizer (paclitaxel) for 4 hours. Phase contrast microscopy images reveal 
morphological differences in live neurons with the various treatments. Blue arrows 
indicate the presence of extensions of the plasma membrane. 
To determine the mechanical impact of MT modification, the Young's modulus (E, a measure of 
stiffness) of individual neurons was mapped by AFM-based force volume imaging (Figure 2A). After 
four hours of treatment with a MT-modifier, neurons were fixed with glutaraldehyde to effectively 
preserve cell surface features [53]. Fixation was necessary due to instrumental limitations, i.e., the 
length of time required to produce a force map, but it is common practice for AFM-based cellular 
experiments, as it improves image resolution and consistency in mechanical          
measurements [43,54–61]. Fixation is known to increase cellular stiffness [43,54]; therefore, these 
studies reflect the relative changes in E. That is, the values of E reported in this study are not 
biologically accurate, but fixation allows for fair comparisons of stiffness across samples whereas the 
properties of living cells may change during the mapping process. Relative values of E were 
determined by extracting individual force-distance curves from the mechanical surface maps. Curves 
were selected from two neuronal regions, the soma and the extended processes, to produce E 
histograms for each sample (Figure 2B-C). Histograms represent E data extracted from a minimum 
of 9 neurons for each treatment. 
Treatment with 10 µM colchicine for four hours significantly decreased E in the somatic region 
by 31% (Figure 2B). Literature reports on the mechanical effect of colchicine are conflicting. For 
instance, neutrophils treated with similar concentrations of colchicine experienced significant 
stiffening [62]. In NRK fibroblasts, however, no mechanical alteration or change in stress fibers was 
observed after treatment with 100 µM colchicine [63]. Furthermore, vascular smooth muscle cells 
exhibited a significant decrease in cell stiffness when treated with colchicine [64]. Thus, the 
influence of colchicine on cellular mechanics is highly dependent on cell type, the state of cell 
division, and even on the region of the cell. Unlike the somatic region, after colchicine treatment the 
rigidity of the neuronal processes was not significantly different than that of the vehicle-treated 
control (1.8% difference). The effect of softening in the somatic region while retaining stiffness in 
the processes can be related to previous studies on fibroblasts. When aged hamster fibroblasts were 
treated with a microtubule disruptor, centrifugal depolymerization occurred and MT remnants were 
found in the cortical areas [14]. The reasoning for this effect is unknown and could be attributed to 
several factors (aging may disrupt the centrosome, reverse the polarity of MTs, alter the stability of 
the anchorage to the membrane, etc.) [14]. 
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Figure 2. Measuring the Young's modulus of neurons treated with MT modifiers. (a) 
Examples of Young's modulus (E) maps obtained by force volume imaging. Histograms 
of the average value of E were constructed by extracting values from the (b) soma or (c) 
processes of neurons treated with: the vehicle or MT-altering drug (colchicine, 
nocodazole, paclitaxel) for 4 hours. Measurements represent the mean E ± standard 
deviation. The ellipses represent regions from which the soma measurements were 
sampled and the arrows indicate where measurements of the processes were sampled. 
Unlike colchicine, when cells were treated with 10 µM nocodazole, the stiffness of the soma 
and processes increased by 39% and 50%, respectively, as compared to the vehicle-treated control 
(Figure 2B-C). This is in agreement with findings from similar studies on L929 fibroblast-like cells 
where an increase in cellular stiffness was observed after treatment with nocodazole [65]. This was 
attributed to the reorganization of the cytoskeletal network after MT depolymerization. Cytoskeletal 
reorganization after injury was observed in Swiss 3T3 cells; when cells were treated with MT 
disruptors, actin polymerization occurred in a dose- and time-dependent manner [66]. These findings 
demonstrate that cell stiffening after nocodazole-induced MT disruption is a consequence of actin 
polymerization. The discrepancy in mechanical changes between colchicine and nocodazole treated 
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neurons may arise from the binding mechanisms to tubulin. Although nocodazole binds tubulin more 
rapidly than colchicine, colchicine binding is irreversible [67], which may explain the variation in 
cellular stiffness between the two treatments. 
 
Figure 3. Assessment of the Aβ1-42 aggregation state. (a) Oligomeric aggregates were 
observed when 5 µM Aβ1-42 was spotted onto freshly cleaved mica and analyzed via ex 
situ AFM imaging after 0, 24 or 48 hours of incubation at 37 °C in a physiologically 
relevant buffer. (b) The thioflavin T assay was performed to detect the presence of 
β-sheet, a characteristic of fibrils. The red line corresponds to 5 µM Aβ which was 
prepared as described in the methods section, and the black line represents 47 µM 
Aβ1-42 obtained from the SensoLyte® Aggregation kit and prepared as recommended by 
the manufacturer. (c) Fibrillar aggregates were observed when 47 µM Aβ1-42 was 
imaged via ex situ AFM after 48 hours of incubation. 
When neurons were treated with 10 µM paclitaxel, rigidity increased by 101% and 89% in the 
somatic region and the processes, respectively, compared to the vehicle-treated control sample 
(Figure 2B-C). Our results are consistent with a similar study, in which cellular stiffening occurred in 
cortical neurons when treated with 10 µM paclitaxel [68]. Although other studies have demonstrated 
that MT-disruption may produce an increase in cellular stiffness by activating a secondary response 
of actin polymerization, paclitaxel-mediated MT stabilization was not reported to stimulate actin 
production [66,69]. Therefore, the increase in cellular stiffness is likely due to the mechanical 
stabilization of the MT network. Taken together, these studies confirmed that a four hour exposure to 
MT modifiers altered the morphology and the mechanical stiffness of neurons. 
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3.2. Microtubule disruption reduces Aβ1-42 binding to the cell membrane 
Before investigating how MT modification influences Aβ1-42-induced cytotoxicity, it was 
necessary to characterize aggregation state of Aβ1-42 that the cells would be exposed to in this study. 
This is critical because the extent of membrane affinity [70,71] and the resulting toxicity [72] is 
dependent on Aβ aggregation state. A fresh Aβ1-42 solution was prepared from lyophilized peptide 
using the Stine preparation method [42]. The solution was diluted to 5 µM, and the aggregation state 
of the peptide was determined by ex situ AFM imaging at 0, 24, and 48 h of incubation (Figure 3A). 
Over the 48 h incubation, only oligomeric aggregates were observed (even at 0 h of incubation); 
however, these oligomers increased in number over 24 h. After 24 h, the number of oligomers 
remained relatively steady. Oligomers increased in size from an average height of 3.0 ± 1.3 nm to 4.2 
± 1.2 nm over the 48 h period as well. The size of Aβ1-42 oligomers can vary considerably 
depending on the preparation method, but the height is consistent with previously observed large 
Aβ1-42 oligomers [73–75]. Elongated fibrillar aggregates were not observed in any 5 µM sample 
within 48 h. The absence of fibrils in the 5 µM solution was confirmed by a Thioflavin T (ThT) 
fluorescence assay, which is based on the interaction between ThT and β-sheet secondary structure, a 
characteristic of amyloid fibrils (Figure 3B). As a positive control, ThT assays were performed on a 
solution of 47 µM Aβ1-42 guaranteed to form fibrils by the manufacturer, and this solution caused an 
immediate increase in fluorescence intensity, consistent with rapid fibril formation and elongation. 
Fibril formation within the 47 µM Aβ1-42 solution was confirmed by AFM (Figure 3C). Cells were 
only exposed to freshly-prepared 5 µM monomeric/oligomeric Aβ1-42 solutions. 
It has been demonstrated that cells may exhibit resistance to Aβ-membrane binding based on 
specific cellular characteristics, such as the presence of apoptotic signaling molecules, cell size, stage 
of the cell cycle, and cytosolic ATP levels [46]. Specifically, when PC-12 cells or GT1-7 neurons 
were exposed to FITC-Aβ1-42, the cells could be divided into three distinct subpopulations based on 
their susceptibility to Aβ binding (those with no binding affinity, high binding affinity, or extra-high 
binding affinity) [46]. Considering this, we wanted to determine if altered neuronal morphology and 
mechanical stiffness from MT modification altered the susceptibility of GT1-7 cells to Aβ1-42 
binding. GT1-7 cells were pretreated with a MT-modifier or a vehicle control (DMSO) for four hours 
and then were exposed to 5 µM FAM-Aβ1-42 solution for 80 minutes. The FAM-Aβ1-42 solution 
contained a mixture of monomer and oligomers, but no fibrils. Pretreatments were not removed from 
the culture medium during the additional 80 minute incubation to prevent MT recovery. After the 80 
minute FAM-Aβ1-42 exposure, aggregate-membrane binding was evaluated by flow cytometry 
(Figure 4A). Approximately 0.2% of the vehicle-treated control had positive staining, which may be 
attributed to the natural fluorescence of the living neurons, likely due to flavoproteins that have a 
similar emission wavelength as FAM-Aβ1-42 (~ 521 nm) [76]. Excluding the vehicle-treated control 
which received no FAM-Aβ1-42 exposure, the vast majority of the neurons in each sample 
population had membrane bound FAM-Aβ1-42 (Figure 4A); however, Aβ binding for the entire 
sample population was slightly lower for neurons pretreated with colchicine (95.2 ± 0.5%, p < 0.01 
to 0.001) and nocodazole (96.5 ± 0.1%, p < 0.001) than those treated with the FAM-Aβ1-42 only 
(98.4 ± 0.1%). The population of neurons pretreated with paclitaxel experienced a similar level of 
aggregate-membrane binding (98.5 ± 0.1%, p > 0.05) as the FAM-Aβ1-42 control. This contrasts 
results from the previously mentioned study [46], and the discrepancy between the 
aggregate-membrane binding is likely due to the peptide preparation technique, as it has been 
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demonstrated that different aggregate species elicit distinctive membrane interactions [77].  
While FAM-Aβ1-42 bound over 95% of cells with or without modified MT networks, the 
amount of FAM-Aβ1-42 bound per cell was affected by MT modification (Figure 4B). Pretreatment 
with paclitaxel did not significantly alter the amount of FAM-Aβ1-42 bound per cell compared to 
control cells with unaltered MT networks; however, neurons pretreated with colchicine and 
nocodazole were bound by approximately 45% less peptide per cell. This decrease in 
peptide-membrane binding likely occurred due to the compromised state of neurons with disrupted 
MT networks. Although the extended processes of the MT disrupted cells were morphologically 
altered (Figure 1), the reduced amount FAM-Aβ1-42 per cell does not appear to be a consequence of 
reduced cellular surface area available for binding due to altered cell size and shape associated with 
MT disruption. The available cellular surface area for cells with unaltered or altered MT networks 
was estimated by measuring the area occupied by cells using fluorescence microscopy and no 
statistical difference was observed between treatments. 
 
Figure 4. The extent of aggregate-membrane binding determined by flow cytometry. (a) 
The percentage of cells in each population that had membrane bound Aβ1-42. (b) The 
amount of aggregate-membrane binding per cell. Neurons were treated with a vehicle or 
various MT-altering drugs (colchicine, nocodazole, paclitaxel) for 4 hours followed by an 
80 minute incubation with FAM-Aβ (with the exception of the vehicle control). Cells 
were extensively rinsed in physiological buffer to remove any unbound Aβ before 
analysis. Measurements were made in triplicate, with 20,000 events per sample. Marker 
(*) represents intensities found to be statistically different (p < 0.05) from the Aβ control 
and error bars represent standard error of the mean (SEM). 
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Figure 5. Measuring the Young's modulus of neurons treated with a MT modifier and 
Aβ1-42. (a) Maps of Young's modulus obtained by force volume imaging. Histograms of 
the average value of E were constructed by extracting values from the (b) soma or (c) 
processes of neurons treated with: the vehicle or MT-altering drug (colchicine, 
nocodazole, paclitaxel) for 4 hours followed by a 30 minute exposure to oligomeric 
Aβ1-42. Measurements represent the mean E ± standard deviation. The ellipses represent 
regions from which the soma measurements were sampled and the arrows indicate where 
measurements of the processes were sampled. 
3.3. Exposure to Aβ1-42 alters neuronal rigidity 
Numerous studies have demonstrated that Aβ causes membrane disruption, which can lead to 
structural and functional cellular changes [78–84]. To determine if Aβ1-42 binding affects the 
mechanical stability of neurons, surface maps of E were produced by force volume imaging. Neurons 
were pretreated with a MT modifier or vehicle (DMSO) for four hours prior to a 30 minute exposure 
to fresh preparations of 5 µM Aβ1-42. The preparations of Aβ1-42 consisted of a mixture of 
monomeric and oligomeric species but did not contain fibrils. Again, the MT modifiers were not 
removed from the culture medium to prevent MT recovery. For all sample populations, the E of the 
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soma and processes significantly increased upon Aβ1-42 exposure compared to control cells that 
were treated similarly in regards to their MT networks but not exposed to Aβ (Figure 5, which can be 
compared directly with Figure 2, and Table 1). Interestingly, stiffening occurred regardless of the 
initial state of the MT network at the time of exposure. A similar stiffening effect was reported 
previously, where an increase in cell stiffness was observed after exposure to 5 µM oligomeric 
Aβ1-42 solutions for 30 minutes [85]. 
Table 1. Percent difference in Young's modulus (E) after 30 minute exposure to Aβ1-42.  
 Soma (% change) Processes (% change) 
Control 142 154 
+ Colchicine 143 29 
+ Nocodazole 
+ Paclitaxel 
69 
88 
19 
77 
Percent differences were calculated for both the soma and neuronal processes. E increased 
significantly in each neuronal region after treatment, with p < 0.001 
3.4. Microtubule disruption reduces the ability of neurons to cope with Aβ1-42 exposure 
Next, we examined the influence of MT disruption on the ability of GT1-7 cells to cope with 
exposure to Aβ1-42. Plasma membrane (PM) degradation and MTT reduction assays were used, as 
these assays are effective tools for assessing Aβ-induced toxicity [72,86–90]. Neurons were 
pretreated with an MT-disruptor (colchicine or nocodazole) or the vehicle (DMSO), at concentrations 
ranging from 0.1 to 10 µM for 4 hours, and then Aβ1-42 (5 µM final concentration) was added to the 
culture medium for an additional 24 to 48 hours. Again, the preparations of Aβ1-42 consisted of a 
mixture of monomeric and oligomeric species but did not contain fibrils. As an important note, the 
amount of PM degradation or MTT reduction for each sample is plotted relative to the control, i.e., 
the total amount of PM degradation or MTT reduction for neurons that were treated with only the 
vehicle (DMSO). 
When neurons were exposed to 0.1–10 µM colchicine, there was no statistical difference in the 
PM degradation induced by the various colchicine concentrations at each respective time point 
(white bars to the left, Figure 6A). However, when neurons were pretreated with colchicine at each 
concentration and then exposed to Aβ1-42 for an additional 24 or 48 hours (gray bars in the center), 
PM degradation significantly increased by 2.25–3.02 times as compared to the neurons that received 
only a colchicine treatment for 28 or 52 hours. In some cases, neurons with a coexposure to both 
colchicine and Aβ1-42 (gray bars in the center), experienced 1.30–1.59 times more PM degradation 
than samples exposed to Aβ1-42 alone (black bars to the right). This demonstrates that MT 
disruption by colchicine enhances the toxicity of Aβ1-42 aggregates, especially considering that the 
neurons with disrupted MTs were bound by half as much Aβ compared to neurons without MT 
disruption as assessed by flow cytometry (Figure 4B). 
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Figure 6. Cellular response to Aβ1-42 after colchicine treatment. (a) PM degradation and 
(b) MTT reduction was evaluated after neurons were pretreated with the vehicle (DMSO), 
or MT-destabilizing drug (colchicine) followed by a 24 or 48 hour exposure to 5 µM Aβ. 
Bars are plotted as relative to the vehicle control (1.0). White bars represent neurons 
treated with colchicine only, gray bars represent treatment with both colchicine and 
Aβ1-42, and black bars represent treated with Aβ1-42 only. The concentration of the drug 
treatment is shown in the legend of (a). The (*) represents samples found to be 
statistically different from neurons only treated with colchicine, and the (+) indicates 
samples that are statistically different from the Aβ1-42 exposed control (p < 0.05). Error 
bars represent standard error of the mean (SEM). PM degradation or MTT reduction for 
each sample is plotted relative to the total amount of PM degradation or MTT reduction 
for neurons that were treated with only the vehicle (DMSO). 
There was little difference in MTT reduction of the neurons exposed to 0.1 µM colchicine, 
Aβ1-42, or coexposure to both agents after 24 hours of treatment (Figure 6B). However, with 
exposure to higher concentrations of colchicine (or longer exposures to 0.1 µM colchicine) with or 
without the presence of Aβ1-42, the MTT response significantly decreased by 22–77% compared to 
neurons that were exposed only to Aβ1-42. This supports the findings from the plasma membrane 
degradation study; MT disruption by colchicine reduces neuronal viability, and therefore, the neurons 
are unable to efficiently cope with even low levels of membrane bound Aβ1-42 as was determined by 
flow cytometry (Figure 4B). 
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Figure 7. Cellular response to Aβ1-42 after nocodazole treatment. (a) PM degradation 
and (b) MTT reduction was evaluated after neurons were pretreated with the vehicle 
(DMSO), or MT-destabilizing drug (nocodazole), followed by a 24 or 48 hour exposure 
to 5 µM Aβ1-42. Bars are plotted as relative to the vehicle control (1.0). White bars 
represent neurons treated with nocodazole only, gray bars represent treatment with both 
nocodazole and Aβ1-42, and black bars represent neurons treated with Aβ1-42 only. The 
concentration of the drug treatment is shown in the legend of (a). The (*) represents 
samples found to be statistically different from neurons only treated with nocodazole, 
and the (+) indicates samples that are statistically different from the Aβ1-42 exposed 
control (p < 0.05). Error bars represent standard error of the mean (SEM). PM 
degradation or MTT reduction for each sample is plotted relative to the total amount of 
PM degradation or MTT reduction for neurons that were treated with only the vehicle 
(DMSO). 
Neurons that received treatment with nocodazole experienced slight increases in PM 
degradation as the concentration increased from 0.1–10.0 µM, but that amount was not statistically 
different (white bars to the left, Figure 7A). When neurons pretreated with nocodazole for four hours 
were exposed to Aβ1-42 aggregates for an additional 24 or 48 hours, PM degradation increased 
significantly by 2.00–4.62 times for cells treated with 0.1 and 1.0 µM nocodazole at 24 and 48 hours, 
as compared to the neurons receiving only a 0.1 or 1.0 µM nocodazole treatment. Neurons pretreated 
with 10 µM nocodazole followed by an exposure to Aβ1-42 for an additional 24 hours did not 
experience a statistically significant increase in PM degradation as compared to those exposed to 10 
µM nocodazole alone. This result is likely due to the fact that 10 µM nocodazole itself is 
considerably more toxic than the lower concentrations of the drug. 
Interestingly, the MTT reduction of neurons exposed to nocodazole, Aβ1-42, or a combination 
thereof for 24 hours was essentially analogous (Figure 7B). After 48 hours of coexposure to 1.0 µM 
nocodazole and Aβ1-42 (gray bar in the center), MTT response decreased nearly by half, as 
compared to the neurons treated with Aβ1-42 only (black bars to the right). Considering that neurons 
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pretreated with nocodazole experienced only half as much aggregate-membrane binding as assessed 
by flow cytometry (Figure 4B), this indicates that neurons with disrupted MTs had a reduced ability 
to cope with exposure to toxic Aβ1-42. After 48 hours, treatment with 10 µM nocodazole alone or a 
combination of nocodazole and Aβ1-42 reduced MTT response by over half of that caused by 
treatment with only Aβ1-42, indicating that nocodazole itself can cause a large reduction in MTT 
response at high concentrations. 
Overall, nocodazole decreased the ability of GT1-7 cells to cope with exposure to Aβ in a 
similar fashion as colchicine; however, the toxic effects were less severe in the nocodazole treated 
samples. This could be attributed to the different binding mechanisms of the MT disruptors to tubulin, 
which produce distinct mechanical responses, or a reduction in axonal transport and signaling caused 
by the breakdown of MTs. In any case, the MT disrupted samples treated with Aβ1-42 aggregates 
experienced just as much, or in some instances, greater toxicity than neurons treated with Aβ1-42 
alone, despite having a reduced amount of Aβ directly interacting with the cell (reduced membrane 
binding, Figure 4B). This result suggests that MT disruption interferes with the cellular response 
mechanisms to Aβ1-42-mediated toxicity, impairing a cell’s ability to efficiently cope with exposure 
to Aβ1-42. 
3.5. Microtubule stabilization delays the onset of Aβ1-42-induced toxicity 
Next, we determined the effect of MT stabilization on the ability of GT1-7 cells to cope with 
exposure to Aβ1-42. Neurons were pretreated with paclitaxel at concentrations ranging from 0.1–10 
µM for 4 hours, and then 5 µM Aβ1-42 was added to the culture medium for an additional 24 to 48 
hours. The preparations of Aβ1-42 consisted of a mixture of monomeric and oligomeric species but 
did not contain fibrils. Control cells were treated with the DMSO vehicle prior to exposure to Aβ1-42. 
Neurons receiving treatment with paclitaxel alone did not experience any statistical difference in PM 
degradation (white bars to the left, Figure 8A). However, PM degradation significantly increased by 
2.88–4.31 times when neurons were pretreated with paclitaxel and then exposed to Aβ1-42 (gray bars 
in the center). Interestingly, at 24 hours, the PM degradation caused by coexposure to paclitaxel and 
Aβ1-42 was half of that induced by Aβ1-42 alone (black bars to the right). This effect was lost after 
48 hours of treatment. This indicates that MT-stabilization by paclitaxel may be able to delay the 
onset of cytotoxicity mediated by Aβ1-42. 
There was no statistical difference in the MTT reduction of neurons exposed to paclitaxel at 0.1 
or 1.0 µM, Aβ1-42, or a combination thereof (Figure 8B). However, the MTT response of neurons 
treated with 10 µM paclitaxel was 1.30–2.33 times higher than any other population after 24 and 48 
hours. This likely occurred because the MT network is highly associated with mitochondrial shape, 
movement and function [91–94], and its stabilization could promote mitochondrial activity. For 
example, hyperphosphorylation of Tau, which is a critical component to MT stabilization, inhibited 
mitochondrial function in PC-12 cells and mouse brain cortical neurons [95]. Thus, it is not 
unreasonable to observe an increase in MTT response after MT-stabilization. Nevertheless, there was 
no significant difference in MTT reduction between neurons coexposed to paclitaxel (at all 
concentrations) and Aβ1-42, or neurons treated with the peptide solution only. Combined with results 
of the plasma membrane degradation assay, this data suggests that MT-stabilization can improve the 
cellular response mechanisms ability to cope with the Aβ1-42 exposure, as the amount of Aβ bound 
per cell treated with paclitaxel was similar to control cells as was assessed by flow cytometry (Figure 
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4B). 
 
Figure 8. Cellular response to Aβ1-42 after paclitaxel treatment. (a) PM degradation and 
(b) MTT reduction was evaluated after neurons were pretreated with the vehicle (DMSO), 
or MT-stabilizing drug (paclitaxel) followed by a 24 or 48 hour exposure to 5 µM 
Aβ1-42. Bars are plotted as relative to the vehicle control (1.0). White bars represent 
neurons treated with paclitaxel only, gray bars represent treatment with both paclitaxel 
and oligomeric Aβ1-42, and black bars represent neurons treated with Aβ1-42 only. The 
concentration of the drug treatment is shown in the legend of (a). The (*) represents 
samples found to be statistically different from neurons only treated with paclitaxel, and 
the (+) indicates samples that are statistically different from the Aβ1-42 exposed control 
(p < 0.05). Error bars represent standard error of the mean (SEM). PM degradation or 
MTT reduction for each sample is plotted relative to the total amount of PM degradation 
or MTT reduction for neurons that were treated with only the vehicle (DMSO) 
4. Discussion 
Our studies sought to determine the role of MT modification on cytotoxicity mediated by 
Aβ1-42 in a non-fibrillar form. That is, preparations of Aβ1-42 used in this study were mixtures of 
monomeric and oligomeric forms of the peptide. While the number of oligomers increased over 24 
hours, fibrils were not observed in the preparations Aβ1-42 for up to 48 h. The role of MT 
modifications on cytotoxicity was accomplished by examining the effects of MT disruption and 
stabilization in GT1-7 neurons exposed to 5 µM Aβ1-42. Although over 95% of neurons in each 
sample treatment group had membrane bound Aβ1-42, MT disruption by colchicine and nocodazole 
significantly reduced the extent of Aβ-membrane binding per cell. The reduction of Aβ-membrane 
binding likely occurred due to the compromised nature of the neurons that received an MT disrupting 
treatment. Alterations in neuronal rigidity caused by MT alterations did not appear to affect 
Aβ-membrane binding; specifically, colchicine reduced neuronal rigidity and nocodazole increased 
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neuronal rigidity compared to neurons with unaltered MTs. This contrasting effect was unexpected, 
considering that both colchicine and nocodazole cause MT depolymerization at high   
concentrations [96], but the discrepancy could be due to the differing binding affinities of each drug 
to tubulin, and/or their mechanisms of action. Literature reports on the tubulin binding site(s) for 
nocodazole or colchicine are conflicting based on the species which the tubulin was derived from, 
and experimental designs [67,97–102]; however, a common finding is that nocodazole-tubulin 
binding is reversible, whereas colchicine-tubulin binding is essentially                
irreversible [67,96,98,103–105]. Accordingly, the tight binding of colchicine to tubulin likely 
contributed to the significant softening of the cells, and to the reduced neuronal viability, compared 
to nocodazole treated neurons. In any case, the reduction in neuronal viability caused by either MT 
disruptor enhanced the neurotoxicity of Aβ1-42 in a synergistic way. This is supported by the 
observation that neurons with unaltered MTs had double the amount of membrane bound Aβ per cell 
as determined by flow cytometry, but experienced similar or decreased levels of PM degradation 
compared to the neurons with disrupted MT networks (Figure 9). On the contrary, MT stabilization 
by paclitaxel had a protective effect against Aβ1-42, as there was reduced toxicity after 24 h 
exposure to Aβ1-42 despite having similar amounts of Aβ bound to the cell (Figure 9). 
 
Figure 9. A comparison of the relative PM degradation associated with exposure to 
Aβ1-42 of cells pretreated with MT altering drugs (10 µM treatment) to cells with no 
drug treatment to the amount of Aβ bound per cell as measured by flow cytometry. The 
arrows demonstrate how the relative PM degradation changes from 24 h to 48 h for cells 
treated with colchicine (blue), nocodazole (red), or paclitaxel (green). As the data is 
plotted relative to the measurements associated with cells that were not treated with 
drugs, the position of the untreated cells + Aβ1-42 remains at position (1.0, 1.0). 
The protective effect of MT stabilization against Aβ-induced cytotoxicity on primary neuronal 
cultures has been previously observed [88,106,107]. There, neurons were treated with 0.1 µM 
paclitaxel for 2 hours before exposure to either 10 µM Aβ1-42 or Aβ25-35. Importantly, the Aβ 
solutions used in those studies were prepared by incubations at 37 °C for 24 hours in 10 mM 
Tris-HCl, a preparation technique that is known to produce fibrillar aggregates [42,108]. Furthermore, 
only peptide solutions with greater than 70% β-sheet conformation were utilized in that study, as 
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confirmed by circular dichroism [88,106,107]. Taken together, the observations that 
paclitaxel-mediated MT stabilization was only able to delay toxicity induced by nonfibrillar 
aggregates of Aβ1-42, but protected against higher concentrations of fibril-induced toxicity for 48 
hours supports the literature that smaller aggregates exert a more toxic effect than their fibrillar 
counterparts [72,86,109]. 
Regardless of the MT state (disrupted vs. stabilized), neuronal stiffness significantly increased 
after exposure to Aβ1-42. This increase in stiffness can be related to the previous point that MT 
stabilization only delayed Aβ oligomer-induced toxicity compared to a more sustained protective 
effect against fibrillar aggregates. Studies have demonstrated that oligomeric Aβ1-42 aggregates 
caused higher stiffness in neurons than fibrillar Aβ1-42 [85]; therefore, Aβ1-42-induced increases in 
cell stiffness may be directly related to increased toxicity, as Aβ1-42 oligomers have been shown to 
produce a more toxic effect than fibrils [72,86,109]. The mechanism of increased neuronal stiffness 
can be explained by findings from model membranes and neuronal studies. When model membranes 
were exposed to Aβ1-40, the aggregates caused extensive membrane disruption and decreased the 
mechanical stiffness of the bilayer [110]. In neurons, a mechanical stiffening occurred after N2a 
neuroblastoma cells and HT22 hippocampal neurons were exposed to 5 µM oligomeric Aβ1-42 
solutions for 30 minutes [85]. The observation of mechanical contrast between model membranes 
and whole cells after Aβ exposure is not unjustified, as mechanical measurements on cells account 
for the entire cell system rather than just the membrane. Thus, while the plasma membrane of a cell 
may become disrupted and less stiff after Aβ exposure, overall cell stiffening may be observed due to 
several factors, or a combination thereof. For example, Aβ aggregates may interact with the 
membrane thereby altering the fluidity or creating pores, which could increase intracellular osmotic 
pressure by unregulated ion influx [78,79,83–85]. Furthermore, studies have demonstrated that in 
primary hippocampal neurons, Aβ23-35 and Aβ1-42 (at concentrations greater than 5 µM) exposure 
stimulated the production of stress fibers through the activation of p38MAPK (mitogen-associated 
protein kinase) [111], which could also contribute to overall cell stiffening. Taken together, these 
findings demonstrate that Aβ-membrane interactions may reduce membrane stiffness while 
increasing the overall mechanical rigidity of neurons through a variety of mechanisms. 
MT disruption, a consequence of the normal aging process, enhanced the toxicity of Aβ1-42 
compared to neurons with unaltered or stabilized MTs. This has further pathological implications for 
the cell, as both synthetic and human-derived aggregates of Aβ1-42 stimulated Tau phosphorylation 
in a variety of cell cultures [26,112,113]. Additionally, in vivo studies have demonstrated that 
injection of Aβ1-42 aggregates into the brains of mice and rhesus monkeys caused Tau 
phosphorylation and the formation of NFTs [114,115]. Considering that the physiological role of Tau 
is to modulate MT assembly and stability, Aβ1-42 aggregate-induced phosphorylation disrupts the 
proper functioning of Tau thereby destabilizing MTs. This essentially creates a self-sustaining 
feedback mechanism, where age-related MT disruption enhances the toxic ability of Aβ1-42 
aggregates to trigger the phosphorylation of Tau and further degrade MTs. This mechanism 
eventually causes synaptic dysfunction, neuronal death, and the breakdown of neuronal networks that 
leads to the clinical symptoms of AD. Given the evidence that MTs play such a critical role in AD 
pathology, MT stabilization has been explored as a potential treatment strategy [88,106,107,116–118]. 
Here, we found that treating neurons with the MT stabilizer, paclitaxel, delayed the onset of toxicity 
induced by nonfibrillar Aβ1-42 aggregates, which correlates well with studies demonstrating that MT 
stabilization has a more prolonged protective effect against Aβ1-42 fibrils. 
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5. Conclusion 
We have provided evidence that altered MT networks influence a cell’s ability to cope with 
exposure to oligomeric aggregates of Aβ1-42. While disrupting the MT network decreased the 
amount of Aβ that actually bound to cells, toxicity of Aβ was enhanced by destabilizing MT. In 
contrast, stabilizing MTs resulted in a protective effect. Regardless of the MT state (disrupted vs. 
stabilized vs. unaltered), exposure to Aβ1-42 aggregates resulted in cell stiffening. Our results 
demonstrate that MT modifications can have a direct influence on the toxicity of small Aβ1-42 
aggregates. 
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